Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 19/20 | 0.59 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29489377 | 0.94 | GLP1R (0.60) | GLP1R | |
| SCHEMBL30952344 | 0.91 | GLP1R (0.61) | GLP1R | |
| SCHEMBL29484313 | 0.90 | NPBWR1 (0.55) | GLP1RCXCR4 | |
| SCHEMBL29434536 | 0.88 | GLP1R (0.55) | GLP1R | |
| SCHEMBL30216222 | 0.88 | GLP1R (0.52) | GLP1RCXCR4 | |
| SCHEMBL30063985 | 0.88 | GLP1R (0.54) | GLP1RCXCR4 | |
| SCHEMBL29484311 | 0.85 | GLP1R (0.56) | GLP1R | |
| SCHEMBL29871710 | 0.85 | CTSL (0.53) | GLP1RCXCR4 | |
| SCHEMBL30338573 | 0.85 | GLP1R (0.54) | GLP1RCXCR4 | |
| SCHEMBL29670477 | 0.85 | NPBWR1 (0.56) | GLP1RCXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4585228-A2 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | Apellis Pharmaceuticals, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| CN-118217402-A | Combination therapy for C3 inhibition | 阿佩利斯制药有限公司 | 2024-06-21 | — | — | CN | disclosed |
| US-11510939-B1 | RNAs for complement inhibition | APELLIS PHARMACEUTICALS, INC. (US) | 2022-11-29 | — | — | US | disclosed |
| EP-3660033-B9 | LONG-ACTING COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | APELLIS PHARMACEUTICALS INC (US) | 2022-06-22 | — | — | EP | disclosed |
| EP-2707384-B1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF | APELLIS PHARMACEUTICALS INC (US) | 2022-04-06 | — | — | EP | disclosed |
| US-11291407-B2 | Detection of high risk drusen | APELLIS PHARMACEUTICALS, INC. (US) | 2022-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11291407-B2 | Detection of high risk drusen | EXOSC4, EXOSC5, EXOSC10 | GLP1R 1394/4885CXCR4 881/4885 |
| US-11510939-B1 | RNAs for complement inhibition | SNRPE, RNASE1, SNRPF | GLP1R 4755/4885CXCR4 4149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.